worldwide@absin.cn
  • Sign in or Register
    My account Recent orders Wish list Address management

    Sign out

  • Cart 0
    The latest additions

      0 items in total

      Subtotal $0.00

      Go to cart
    • English
      Chinese
    爱必信(absin)官网
    爱必信(absin)官网

    000000 Citations

    Home
    Products
    Promotions
    Resources
    Product ApplicationFAQsNewsCitationsElectronic DocumentsCalculation Tools
    About us
    Contact us
    worldwide@absin.cn
    • Sign in or Register
      My account Recent orders Wish list Address management

      Sign out

    • Cart 0
      The latest additions

        0 items in total

        Subtotal $0.00

        Go to cart
      • English
        Chinese
      爱必信(absin)官网
      爱必信(absin)官网

      000000 Citations

      Home
      Products
      Promotions
      Resources
      Product ApplicationFAQsNewsCitationsElectronic DocumentsCalculation Tools
      About us
      Contact us
      HomeProduct ApplicationLiterature Review: TME-Activated MXene Nanoheterojunctions Combine Phototherapy and Metabolic Interference to Potentiate Cuproptosis and Antitumour Immunotherapy
      Search

      Literature Review: TME-Activated MXene Nanoheterojunctions Combine Phototherapy and Metabolic Interference to Potentiate Cuproptosis and Antitumour Immunotherapy

      November 16, 2026

      Clicks:77

      Share:
      Share This on facebook
      Share This on twitter
      Share This on pinterest
      Share This on linkedin
      Share This on skype
      Share This on telegram
      Share This on whatsapp
      Share This on wechat

      Literature Review: TME-Activated MXene Nanoheterojunctions Combine Phototherapy and Metabolic Interference to Potentiate Cuproptosis and Antitumour Immunotherapy

      1. Publication Overview

      • Title: TME-activated MXene nanoheterojunctions engineer cancer cells through phototherapy and metabolic interference for enhanced cuproptosis and immunotherapy

      • Journal: Chemical Engineering Journal (CEJ), 2026 (JCR Q1 top journal, latest IF = 12.5, leading venue in chemical engineering and biomaterials)

      • DOI: 10.1016/j.cej.2026.178527

      2. Core Conclusions

      This study develops a folate-targeted Nb2C/CuO2 nanoheterojunction carrier (NbCuF@MR) co-loaded with the immune adjuvant R848 and the metabolic inhibitor methotrexate (MTX). The nanoplatform responds selectively to the tumour microenvironment (acidity, high glutathione concentration) to release copper ions in a targeted manner, and couples this delivery with dual photothermal and photodynamic action under an 808 nm near-infrared laser to amplify oxidative stress. Interference with the mitochondrial TCA cycle induces potent cuproptosis, which concurrently triggers immunogenic cell death (ICD) and remodels the immunosuppressive cold tumour microenvironment, promoting dendritic cell maturation, repolarisation of M2 tumour-associated macrophages towards the M1 phenotype, and extensive infiltration of CD4+ and CD8+ effector T cells. In orthotopic and bilateral 4T1 breast cancer models, a single dosing cycle significantly suppresses primary tumour growth and distant metastasis while establishing durable antitumour immune memory; transcriptomic profiling fully corroborates the coordinated activation of cuproptosis, oxidative stress and immune-related pathways, providing a translatable nanoplatform strategy for cuproptosis-based phot-immunotherapy.

      3. Role of Absin Products in the Study

      The study used Absin Collagenase IV (catalogue number abs47048003) for efficient dissociation of mouse tumour, spleen and lymph node solid tissue into single-cell suspensions. The reagent preserves the activity of cell-surface antigens on immune cells, providing high-quality single-cell suspensions for subsequent flow cytometric immune profiling and single-cell functional analysis of tumour tissue, and thereby ensuring the accuracy and reliability of the in vivo immunophenotyping data.

      4. Field Background

      1. Bottlenecks in cuproptosis. Cuproptosis is a newly defined copper-dependent mitochondrial programme of cell death. Tumour killing is achieved by targeting the mitochondrial lipoylation proteins DLAT, FDX1 and LIAS, but systemic delivery of free copper ions causes toxicity in normal organs. In addition, the high glutathione (GSH) concentration characteristic of tumours chelates copper ions and substantially weakens cuproptosis, while CuO2 nanomaterials have poor intrinsic stability and readily degrade prematurely, limiting their in vivo application and translation.

      2. Core limitations of tumour immunotherapy. Solid tumours are characterised as “cold tumours” in which hypoxia, high GSH, abundant M2 macrophages, scarcity of mature dendritic cells and insufficient effector T cell infiltration together generate a strongly immunosuppressive microenvironment. Immune agonists alone penetrate tumours poorly and fail to initiate durable systemic antitumour immunity.

      3. Advantages and gaps of MXene nanomaterials. Nb2C MXene exhibits excellent near-infrared photothermal conversion, oxygen generation and GSH depletion performance, but MXene alone cannot induce cuproptosis. Existing copper-based nanosystems cannot simultaneously achieve targeted copper delivery, phototherapy enhancement, metabolic reprogramming and immune activation, and a targeted nanoplatform integrating amplified cuproptosis, phototherapy and immunomodulation has been lacking.

      4. Innovation of the present work. Addressing these three bottlenecks, the study constructs for the first time a TME-responsive nanoheterojunction combining Nb2C MXene with CuO2. Folate targeting enables precise copper delivery to tumours, simultaneous loading of R848 and MTX accomplishes metabolic remodelling, and the 808 nm laser amplifies cuproptosis and ICD, establishing a cuproptosis–phototherapy–immunology positive feedback loop and filling the gap in multifunctional cuproptosis nano-immunotherapy materials.

      5. Overall Study Logic

      The work follows an eight-level progression: material synthesis and multi-dimensional physicochemical characterisation; in vitro cellular function verification; mechanistic analysis of cuproptosis and ICD; in vivo biodistribution and single-agent antitumour assessment; tumour microenvironment immune remodelling; bilateral tumour model for distant metastasis and immune memory; transcriptomic confirmation of molecular pathways; and a concluding evaluation of material advantages, translational prospects and long-term toxicity outlook.

      1. CuO2 nanoflowers and Nb2C/CuO2 heterojunctions were synthesised, modified with folate-PEG and loaded with R848 and MTX; TEM, XPS, photothermal and ESR measurements verified the optical and catalytic performance (Fig. 1).

      2. Cellular targeting and cytotoxicity were assessed in 4T1 breast cancer cells, covering folate uptake, ROS generation, mitochondrial damage and apoptotic killing (Fig. 2).

      3. Western blotting quantified the core cuproptosis proteins and confocal microscopy detected ICD markers such as CRT and HMGB1; in vitro dendritic cell maturation assays confirmed immune activation (Fig. 3).

      4. ICP-MS and in vivo fluorescence verified tumour enrichment, and eight treatment groups were evaluated for tumour growth, organ safety and metastasis inhibition (Fig. 4).

      5. Flow cytometry profiled dendritic cells, macrophages and CD4/CD8 T cell infiltration in tumour and draining lymph node, with serum inflammatory cytokines quantified (Fig. 5).

      6. The bilateral tumour model assessed systemic immune suppression, distant metastasis and splenic memory T cell responses (Fig. 6).

      7. RNA sequencing with differential gene, GO, KEGG and GSEA enrichment analysis confirmed the coordinated activation of cuproptosis, oxidative stress and immune pathways at the molecular level (Fig. 7).

      8. Material advantages, clinical translation prospects and long-term toxicity research directions were summarised.

      6. Module-by-Module Analysis

      6.1 Synthesis and physicochemical characterisation of the NbCuF@MR nanoheterojunction

      Logic: CuO2 and the Nb2C heterojunction were constructed step by step, surface-modified with folate-PEG for targeting, and co-loaded with R848 and MTX, with systematic verification of morphology, elemental composition, photothermal behaviour, ROS generation and TME-responsive catalytic activity.

      Core experiments: nanoparticle synthesis; TEM and HAADF-STEM elemental mapping; XPS survey and high-resolution spectra; 808 nm photothermal heating and cycling stability; ESR detection of ·OH and 1O2; catalytic assays under simulated tumour microenvironment conditions.

      Key results:

      • TEM confirmed successful assembly of CuO2 nanoflowers with Nb2C sheets, and elemental mapping showed homogeneous distribution of Nb, Cu and O.

      • XPS verified the presence of Cu2+ and peroxide O–O bonds, demonstrating stable heterojunction formation.

      • NbCuF achieved a photothermal conversion efficiency of 41.48% with no decay over five heating and cooling cycles, and in vivo laser irradiation raised local tumour temperature to 46 °C.

      • ESR demonstrated efficient hydroxyl radical and singlet oxygen generation by the heterojunction, with markedly increased ROS production under acidic, high-GSH tumour microenvironment conditions.

      6.2 In vitro targeted uptake, combined phototherapy and cytotoxicity, and mitochondrial damage

      Logic: folate-mediated selective uptake by tumour cells was verified, and ROS burst under 808 nm laser irradiation, collapse of mitochondrial membrane potential and apoptosis were measured.

      Core experiments: Cy5.5 confocal imaging of uptake; DCFH-DA ROS staining; JC-1 mitochondrial membrane potential assay; Calcein-AM/PI live-dead staining; Annexin V/7-AAD flow cytometric apoptosis analysis.

      Key results:

      • Folate-modified NbCuF achieved substantially higher cellular uptake than non-targeted NbCu, confirming folate receptor targeting specificity.

      • The NbCuF@MR plus laser group showed the highest ROS level, severe loss of mitochondrial membrane potential and an apoptosis rate of up to 96%.

      • The broad-spectrum killing effect was reproduced in two breast cancer cell lines, MDA-MB-231 and BT-474.

      6.3 In vitro activation of the cuproptosis pathway and induction of immunogenic cell death

      Logic: the nanoplatform was shown at the molecular level to induce canonical cuproptosis while releasing DAMPs that activate dendritic cells.

      Core experiments: western blotting for FDX1, LIAS, DLAT and cleaved caspase-9; confocal observation of CRT membrane translocation and extracellular HMGB1 release; bone marrow-derived dendritic cell (BMDC) co-culture with flow cytometric maturation analysis; colony formation inhibition assay.

      Key results:

      • In the NbCuF@MR plus laser group, DLAT oligomerisation was markedly up-regulated while FDX1 and LIAS expression was down-regulated, indicating complete activation of the cuproptosis pathway. The copper chelator TTM reversed cell death, confirming that death depends on copper ions.

      • The combined group showed extensive CRT membrane translocation, HMGB1 release and increased extracellular ATP, indicating potent ICD.

      • Tumour cell supernatants significantly increased the proportion of CD80+CD86+ mature dendritic cells, and colony formation ability was almost completely abolished.

      6.4 In vivo biodistribution, orthotopic 4T1 tumour suppression and organ safety

      Logic: intravenous dosing was used to verify tumour enrichment, and eight controlled groups evaluated in vivo tumour growth inhibition, anti-metastatic effect and biological safety.

      Core experiments: Cy5.5 in vivo fluorescence and ICP-MS quantification of Nb and Cu in organs; group-wise dosing and laser treatment with tumour volume and body weight recorded every other day; H&E, Ki67, TUNEL and CD8 immunofluorescence on tumours; pathological examination of liver metastatic foci.

      Key results:

      • The NbCuF group produced the strongest tumour fluorescence signal, with the highest Nb and Cu accumulation in tumour tissue at 24 h and progressive metabolic clearance from major organs.

      • The NbCuF@MR plus laser group achieved a tumour inhibition rate approaching 90%, with no reduction in mouse body weight and no pathological damage in liver, heart, spleen, lung or kidney.

      • Only the combined group was free of liver metastatic foci, with significant down-regulation of the proliferation marker Ki67, marked elevation of TUNEL apoptosis signal and extensive CD8+ T cell infiltration into tumours.

      Use of the Absin product: Absin Collagenase IV (abs47048003) was used for single-cell preparation from tumour, spleen and draining lymph node tissue. It gently degrades the collagen matrix while fully preserving immune cell surface markers, avoiding excessive digestion that would damage CD4, CD8 or CD86 epitopes, and thereby ensuring accurate downstream flow cytometric data.

      6.5 In vivo remodelling of the tumour microenvironment

      Logic: multi-tissue flow cytometry systematically resolved changes in the immune microenvironment after treatment, verifying the conversion of a cold tumour into a hot tumour.

      Core experiments: spleen, tumour and draining lymph node tissues were digested with Collagenase IV to prepare single-cell suspensions; multicolor flow cytometry resolved CD4+/CD8+ T cells, M1/M2 macrophages and mature dendritic cells; serum TNF-α, IL-6 and IFN-γ were quantified by ELISA; CD8 immunofluorescence was performed.

      Key results:

      • In the NbCuF@MR plus laser group, mature dendritic cells (CD80+CD86+) increased 4.6-fold and intratumoural CD8+ and CD4+ T cells increased 13.7-fold and 5.4-fold respectively.

      • Tumour-associated macrophages completed M2-to-M1 repolarisation, reversing the immunosuppressive microenvironment; serum pro-inflammatory cytokines TNF-α, IL-6 and IFN-γ were significantly elevated, indicating activation of systemic antitumour immunity.

      Use of the Absin product: the entire workflow depended on abs47048003 Collagenase IV for dissociation of solid tumour, lymph node and spleen tissue to obtain high-viability single-cell suspensions, a prerequisite reagent for flow cytometric immune profiling.

      6.6 Bilateral 4T1 model for distant metastasis suppression and durable immune memory

      Logic: a primary plus distant bilateral tumour model was constructed to simulate metastasis and evaluate systemic immune responses and the formation of immune memory.

      Core experiments: bilateral subcutaneous tumour implantation with measurement of tumour volume and weight in each group; CD8 and TUNEL immunofluorescence on tumour tissue; flow cytometric detection of splenic memory T cells (CD44+CD62L−).

      Key results:

      • Growth of both primary and distant tumours was strongly suppressed in the NbCuF@MR plus laser group, with extensive CD8+ T cell infiltration into distant tumours.

      • The proportion of splenic effector memory T cells increased significantly, demonstrating that treatment induced durable immune memory capable of long-term resistance to tumour recurrence and distant metastasis.

      Use of the Absin product: Absin abs47048003 Collagenase IV was used uniformly for dissociation of bilateral tumour and spleen tissue, so that a standardised digestion protocol keeps parallel samples across groups comparable and reduces experimental variation.

      6.7 RNA transcriptome sequencing

      Logic: transcriptome-wide analysis of tumour gene differences after treatment provided molecular pathway evidence for the coordinated activation of cuproptosis, oxidative stress and immune signalling.

      Core experiments: RNA extraction from control and NbCuF@MR plus laser tumours followed by sequencing, with Venn diagram, volcano plot, heat map and KEGG, GO and GSEA enrichment analysis.

      Key results:

      • Differentially expressed genes were enriched in the TCA cycle, the core cuproptosis pathway, glutathione metabolism, apoptosis and the NF-κB oxidative stress pathway.

      • Toll-like receptor signalling, cytokine interactions, T cell differentiation and TNF immune pathways were significantly up-regulated, fully corroborating the immune activation conclusions drawn from the phenotypic experiments.

      7. Overall Contribution of the Absin Product

      1. Gentle and efficient tissue dissociation with antigen protection. Absin Collagenase IV (abs47048003) has low trypsin-like activity and does not disrupt the cell-surface markers CD3, CD4, CD8, CD80, CD86 or CD206 when digesting the connective tissue of tumours, spleens and lymph nodes. This preserves the native phenotype of immune cells to the greatest extent and avoids false-negative flow cytometric results caused by over-digestion.

      2. A standardised reagent for multiple solid tissue types. The enzyme is applicable to mammary tumour, draining lymph node and spleen samples, all of which consist of dense connective tissue. A unified digestion system guarantees stable horizontal comparison of data across orthotopic and bilateral tumour experiments and meets the reproducibility and quality control standards expected by leading journals in the field.

      3. Essential support for the central immunological conclusions. All key flow cytometric data underpinning the findings on M2 macrophage repolarisation, dendritic cell maturation, CD8 effector T cell infiltration and immune memory were obtained from single-cell suspensions prepared with this reagent, making it an indispensable preparatory tool for the material–cuproptosis–immunity mechanism and a reliable basis for the translational claims of the nanoplatform.


      Contact Absin

      Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

      Absin Bioscience Inc.

      worldwide@absin.cn
      Follow us on Facebook: Absin Bio
       
       

      Ordering Details

      Email: worldwide@absin.cn

      Thanks for your interesting of our products, we will reply to you in 1-2 working days.

      • Products
      • Resources
      • Product Application
      • Calculation Tools
      • FAQs
      • Citations
      • Electronic Documents
      • About us
      • Company Profile
      • Ordering Tools
      • Customer Support
      • Contact us
      Email: worldwide@absin.cn
      picture invalid picture invalid
      ICP:16001690 Absin Bioscience Inc.All rights reserved.